Research Topics
| E P BrassSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Changing the status of drugs from prescription to over-the-counter availabilityE P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
N Engl J Med 345:810-6. 2001..Thus, the future promises increases in the number of drugs available over the counter and in the variety of indications for their use...- Carnitine and sports medicine: use or abuse?Eric P Brass
Harbor UCLA Center for Clinical Pharmacology, 1124 West Carson Street, Building J2, Torrance, CA 90502, USA
Ann N Y Acad Sci 1033:67-78. 2004..While data do not allow a conclusion to be drawn that carnitine is beneficial, the negative has not been proven either... 
Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessmentE P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, California, USA
Clin Pharmacol Ther 90:791-803. 2011..The proposed approach has the potential to provide structured, transparent tools for regulatory decision making for nonprescription drugs...- A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudicationEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502, USA
J Vasc Surg 55:381-389.e1. 2012..K-134, a novel phosphodiesterase inhibitor, was evaluated in a phase II trial incorporating an adaptive design to assess its safety, tolerability, and effect on treadmill walking time... 
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudicationRoger J Lewis
Department of Emergency Medicine, Harbor UCLA Medical Center, 1000 West Carson Street, Torrance, California 90509, USA
Trials 12:134. 2011..We describe the design, oversight, and implementation of an adaptive, phase II, dose-finding trial evaluating K-134 for the treatment of stable, intermittent claudication...- Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial diseaseE P Brass
Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90509, USA
Am J Physiol Heart Circ Physiol 280:H603-9. 2001.... - Potential impact on cardiovascular public health of over-the-counter statin availabilityEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, California, USA
Am J Cardiol 97:851-6. 2006..The analyses also identified opportunities for optimizing the use of OTC statins in the marketplace... - Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemiaEric P Brass
Harbor UCLA Medical Center for Clinical Pharmacology, Torrance, California 90502, USA
J Vasc Surg 43:752-9. 2006..The current trial was designed to test the hypothesis that lipo-ecraprost would improve amputation-free survival in patients with CLI who had no revascularization options... - The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial diseaseEric P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, California 90502, USA
J Am Coll Cardiol 48:2539-45. 2006..The current study tested the hypothesis that NM-702 improves treadmill exercise performance in peripheral arterial disease patients with claudication-limited exercise performance... - Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapiesEric P Brass
Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
Vasc Med 11:141-5. 2006..The current analyses provide benchmark data for ensuring that development programs are large enough to allow meaningful safety conclusions, and to assist in data and safety monitoring of these trials... - Optimal assessment of baseline treadmill walking performance in claudication clinical trialsEric P Brass
Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Torrance, CA 90502, USA
Vasc Med 12:97-103. 2007..These characteristics may obviate the need for multiple treadmill tests, potentially saving study costs and improving patient acceptance of trial participation... - Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment StudyEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, California, USA
Am J Cardiol 101:1448-55. 2008..In conclusion, SELECT showed that consumers could use an OTC drug label in an unsupervised setting to appropriately self-select for self-management of their cholesterol with lovastatin... - Analysis of multiple end points in consumer research in support of switching drugs from prescription to over-the-counter status: the concept of end-point hierarchiesE P Brass
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
Clin Pharmacol Ther 85:369-74. 2009.... - Temporal pattern of skeletal muscle gene expression following endurance exercise in Alaskan sled dogsEric P Brass
Department of Medicine, Harbor University of California Los Angeles Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
J Appl Physiol 107:605-12. 2009..RNA expression profiling has the potential to identify novel regulatory mechanisms and responses to exercise stimuli... - Basic biomedical sciences and the future of medical education: implications for internal medicineEric P Brass
Department of Medicine, Harbor UCLA Medical Center and the David Geffen School of Medicine at UCLA, 1124 W Carson Street, Torrance, CA 90502, USA
J Gen Intern Med 24:1251-4. 2009..Internists should be engaged in the ongoing discussions of medical education reform and provide a strong voice in support of rigorous scientific training for the profession... - Considerations in the development of drugs to treat sarcopeniaEric P Brass
Department of Medicine, Harbor University of California at Los Angeles Medical Center, Torrance, California, USA
J Am Geriatr Soc 59:530-5. 2011..Each potential endpoint has advantages and disadvantages from scientific, clinical, and regulatory perspectives that must be carefully considered in the design of trials for sarcopenia treatments... - Consumer behavior in the setting of over-the-counter statin availability: lessons from the consumer use study of OTC MevacorEric P Brass
Department of Medicine, Center for Clinical Pharmacology, Harbor UCLA Medical Center, Torrance, California 90502, USA
Am J Cardiol 94:22F-29F. 2004..These data are important for making an informed risk-benefit decision concerning OTC statin availability... - Pivalate-generating prodrugs and carnitine homeostasis in manEric P Brass
Department of Medicine, Harbor University of California Los Angeles Medical Center, Torrance, California 90502, USA
Pharmacol Rev 54:589-98. 2002..In contrast, long-term treatment with substantial doses of pivalate prodrugs may require administration of carnitine supplementation to avoid carnitine depletion... - Label development and the label comprehension study for over-the-counter drugsEric P Brass
Department of Medicine, Center for Clinical Pharmacology, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
Clin Pharmacol Ther 74:406-12. 2003 - Peripheral arterial disease is not associated with an increased prevalence of intradialytic cramps in patients on maintenance hemodialysisEric P Brass
Department of Medicine, Harbor UCLA Medical Center, Torrance, Calif 90502, USA
Am J Nephrol 22:491-6. 2002..Peripheral arterial disease (PAD) has been suggested as a contributing factor to the development of intradialytic muscle cramps in patients on maintenance hemodialysis... - Implications of a switch from prescription to over-the-counter status for allergy drugsEric P Brass
Department of Medicine, Harbor UCLA Center for Clinical Pharmacology, 1124 W Carson Street, Tornace, CA 90502, USA
Curr Allergy Asthma Rep 4:245-50. 2004..Therefore, although OTC access to allergy medications facilitates treatment of allergies by consumers, more research is required to understand the true public health and economic impacts of OTC availability of these drugs... - Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxilEric P Brass
Harbor UCLA Center for Clinical Pharmacology, Torrance, CA 90502
Clin Pharmacol Ther 73:338-47. 2003..To evaluate the effect of pivalate prodrug treatment on carnitine homeostasis, we administered a pivalate prodrug, cefditoren pivoxil, to healthy subjects and performed carnitine balance studies... - Intravenous L-carnitine increases plasma carnitine, reduces fatigue, and may preserve exercise capacity in hemodialysis patientsE P Brass
Department of Medicine, Harbor University of California at Los Angeles Medical Center, Torrance, CA 90509, USA
Am J Kidney Dis 37:1018-28. 2001..VO(2max) in the primary analysis and other assessed end points were unaffected by carnitine therapy... - Clinical and demographic predictors of exercise capacity in end-stage renal diseaseKathy E Sietsema
Department of Medicine, Harbor UCLA Research and Education Institute, Torrance, CA, USA
Am J Kidney Dis 39:76-85. 2002.... - Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matricesMichael R Yeaman
Department of Medicine, Division of Infectious Diseases, Harbor UCLA Medical Center, Research and Education Institute at Harbor UCLA, Torrance, California 90502, USA
Antimicrob Agents Chemother 46:3883-91. 2002..Collectively, these findings support the concept that synthetic peptides can be designed to exert potent antimicrobial activities in relevant and complex biological matrices... - Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussionEric P Brass
Center for Clinical Pharmacology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA
Vasc Med 9:293-301. 2004..The relative contribution of these factors and their role in the pathophysiology of the exercise limitation is discussed using a point-counterpoint approach. Future directions for research conclude the discussion... - Skeletal muscle StO2 kinetics are slowed during low work rate calf exercise in peripheral arterial diseaseTimothy A Bauer
Department of Medicine, University of Colorado at Denver Health Sciences Center, Box B 179, 4200 East Ninth Avenue, Denver, CO 80262, USA
Eur J Appl Physiol 100:143-51. 2007.... - Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular riskEric P Brass
Department of Medicine, Section of Vascular Medicine, University of Colorado Health Sciences Center, Colorado Prevention Center, and National Jewish Medical and Research Center, Denver, 80203, USA
Clin Pharmacol Ther 79:165-72. 2006 - Potential biomarkers of muscle injury after eccentric exerciseKathy E Sietsema
Harbor UCLA Medical Center, Torrance, CA, USA
Biomarkers 15:249-58. 2010..ACT and C1 Inh peptides peaked earlier post-exercise than creatine kinase, and thus appear to provide new information on muscle response to injury... - Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal diseaseKathy E Sietsema
Harbor UCLA Research and Education Institute, Torrance, CA 90502, USA
Kidney Int 65:719-24. 2004..We analyzed the value of exercise capacity, characterized as peak oxygen uptake (VO2), for predicting survival in a cohort of 175 hemodialysis patients over a median follow-up of 39 months... - Trends in antimicrobial drug development: implications for the futureBrad Spellberg
Research and Education Institute and Department of Medicine, Harbor-University of California, Los Angeles Medical Center, Torrance, California 90502, USA
Clin Infect Dis 38:1279-86. 2004..Despite the critical need for new antimicrobial agents, the development of these agents is declining. Solutions encouraging and facilitating the development of new antimicrobial agents are needed... - Differential management of cardiovascular disease in ESRD by nephrologists and cardiologistsHamik A Martirosyan
Division of Nephrology and Hypertension, Harbor-University of California, Los Angeles Research and Education Institute, Torrance, CA, USA
Am J Kidney Dis 44:309-21. 2004..The discipline-driven differential management approaches observed emphasize the need for better evidence-based management strategies for this population... - Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects)William R Hiatt
Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, University of Colorado School of Medicine C O Colorado Prevention Center, Denver, CO 80203, USA
J Vasc Surg 47:330-336. 2008..At the time of approval, the United States Food and Drug Administration required an additional long-term safety study to evaluate the effect cilostazol on mortality... - American and German students' knowledge, perceptions, and behaviors with respect to over-the-counter pain relieversYaniv Hanoch
Department of Health Services, UCLA School of Public Health, University of California Los Angeles, CA, USA
Health Psychol 26:802-6. 2007..The authors expected that the differences in access and marketing would affect knowledge and decision making related to OTCPRs in the United States and Germany... - Adjunctive parenteral therapy with lipo-ecraprost, a prostaglandin E1 analog, in patients with critical limb ischemia undergoing distal revascularization does not improve 6-month outcomesMark R Nehler
University of Colorado Health Sciences Center and the Colorado Prevention Center, Denver, CO 80262 0302, USA
J Vasc Surg 45:953-60; discussion 960-1. 2007.... - Pulmonary VO2 dynamics during treadmill and arm exercise in peripheral arterial diseaseTimothy A Bauer
Section of Vascular Medicine, University of Colorado Health Sciences Center, Box B-179, 4200 East Ninth Ave, Denver, CO 80262, USA
J Appl Physiol 97:627-34. 2004..Furthermore, the slowed pulmonary Vo(2) kinetics of the lower extremity could not be explained by any abnormalities in resting cardiac or pulmonary function and were not related to the magnitude of reduction in limb vascular reactivity... - Impaired muscle oxygen use at onset of exercise in peripheral arterial diseaseTimothy A Bauer
University of Colorado Health Sciences Center, Denver 80262, USA
J Vasc Surg 40:488-93. 2004..Impaired muscle metabolism may contribute to the altered physiologic responses to exercise and to exercise impairment in patients with PAD... - Carnitine replacement in end-stage renal disease and hemodialysisMenotti Calvani
Sigma Tau, Via Pontina Km 30, 00400 Pomezia, Rome, Italy
Ann N Y Acad Sci 1033:52-66. 2004..Furthermore, LC may positively influence the nutritional status of HD patients by promoting a positive protein balance, and by reducing insulin resistance and chronic inflammation, possibly through an effect on leptin resistance...